Thursday, July 14, 2011
Bristol-Myers Squibb returns another cancer drug to Exelixis
Bristol-Myers Squibb is returning rights to an experimental cancer drug to Exelixis Inc. — the second time it has sent a drug back to the South San Francisco biotech company in little more than a year.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment